Tirzepatide peptide is a first-in-class dual GIP and GLP-1 receptor agonist, also called a twincretin.
Tirzepatide peptide is a first-in-class dual GIP and GLP-1 receptor agonist, also called a twincretin. This 39-amino-acid synthetic peptide activates both incretin receptors to raise glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite. A C20 fatty diacid extends half-life for once-weekly study and use. Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea, tirzepatide produced major HbA1c and body-weight reductions in SURPASS and SURMOUNT trials, often exceeding selective GLP-1 peptides such as semaglutide. This video explains tirzepatide structure, mechanism of action, research applications, and how it compares with other metabolic peptides.